Masimo (NASDAQ:MASI) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Masimo Co. (NASDAQ:MASI) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $138.22 and traded as high as $169.66. Masimo shares last traded at $168.80, with a volume of 634,326 shares changing hands.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on MASI shares. Needham & Company LLC restated a “hold” rating on shares of Masimo in a research report on Wednesday, November 6th. Wells Fargo & Company lifted their price target on Masimo from $171.00 to $193.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. Piper Sandler raised their target price on shares of Masimo from $180.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. BTIG Research boosted their target price on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Finally, Raymond James raised their target price on Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $179.67.

Masimo Trading Down 1.4 %

The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a 50-day simple moving average of $168.12 and a 200 day simple moving average of $138.69. The company has a market capitalization of $8.91 billion, a P/E ratio of 114.77 and a beta of 1.01.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the prior year, the business posted $0.63 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Sell-side analysts expect that Masimo Co. will post 4.03 earnings per share for the current year.

Hedge Funds Weigh In On Masimo

Large investors have recently made changes to their positions in the company. NBC Securities Inc. lifted its stake in shares of Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Masimo by 133.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Masimo by 136.5% during the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after buying an additional 269 shares during the period. Headlands Technologies LLC acquired a new stake in shares of Masimo in the 2nd quarter valued at approximately $109,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Masimo during the third quarter valued at approximately $118,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.